(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
5 Breakout Stars in Ongoing television Series - 2In vogue Sleepwear Patterns for 2024
- 3Step by step instructions to Figure out the Natural Effect of 5G Pinnacles
- 4The Manual for Well known rough terrain Vehicles
- 5Step by step instructions to Choose the Right Internet based Degree Program for Your Future
- Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- Man threatens attack on German high-speed train, injures several
- Two reportedly killed as Israel attacks Hezbollah targets in Lebanon
- The Most Important Crossroads in Olympic History
- In these U.S. groups, deaths now exceed births. What’s happening?
- Vote In favor of Your Favored Video Conferencing Administration
- Sudan war ‘being fought on women’s bodies’: Survivors detail sexual assault
- ADHD drugs work, but not the way experts thought
- The Best Business visionaries Under 30
